**Evidence Table I-15. Adverse events in studies comparing vasoactive agents versus other interventions for the prevention of contrast induced nephropathy**

|  |  |
| --- | --- |
| **Author, Year** | **Adverse events** |
| Allaqaband,2002[5](#_ENREF_5" \o "Allaqaband, 2002 #2899) | Other: Hypotension; Fenoldopam reaction. Definition not reported |
| Briguori,2004[10](#_ENREF_10" \o "Briguori, 2004 #2576) | Other: Hypotension; Allergic reaction; skin rash and vomiting |
| Demir,2008[16](#_ENREF_16" \o "Demir, 2008 #8303) | NR |
| Gunebakmaz, 2012[21](#_ENREF_21) | NR |
| Li, 2011[39](#_ENREF_39) | NR |
| Li, 2014 [40](#_ENREF_40) | NR |
| Liu, 2013[41](#_ENREF_41) | Major event (cardiac death, non-fatal MI, ischemic stroke): Arm1: 8, Arm2: 3  ESRD, revascularization, CABG, CHF, pulmonary edema, need for permanent pacing: Arm1: 18, Arm2: 7  AE incidence within 6 months of the procedure were significantly lower in the aloprostadil group (p=0.035). |
| Ng, 2006[50](#_ENREF_50) | No patient had any adverse event in any arm |
| Oguzhan, 2013[51](#_ENREF_51) | NR |
| Talati, 2012[62](#_ENREF_62) | Other: Hypotension; NR |
| Wolak, 2013[65](#_ENREF_65) | NR |

NR=not reported